Artivion, Inc. $AORT Shares Sold by Royce & Associates LP

Royce & Associates LP reduced its position in Artivion, Inc. (NYSE:AORT) by 18.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 432,782 shares of the company’s stock after selling 96,965 shares during the quarter. Royce & Associates LP’s holdings in Artivion were worth $19,739,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Aster Capital Management DIFC Ltd boosted its holdings in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion in the third quarter valued at approximately $27,000. Larson Financial Group LLC boosted its holdings in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the period. USA Financial Formulas boosted its holdings in shares of Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Artivion in a report on Wednesday, May 20th. Canaccord Genuity Group decreased their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Stifel Nicolaus set a $55.00 price target on Artivion in a report on Thursday, March 5th. Needham & Company LLC decreased their price target on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Artivion has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Artivion Price Performance

Shares of NYSE AORT opened at $23.21 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. The stock has a fifty day moving average price of $32.83 and a 200 day moving average price of $39.23. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a market cap of $1.13 billion, a PE ratio of 96.71 and a beta of 1.41.

Insider Activity

In other Artivion news, EVP Lance A. Berry sold 6,316 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $238,618.48. Following the completion of the transaction, the executive vice president owned 210,827 shares in the company, valued at approximately $7,965,044.06. This represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Amy Horton sold 901 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $34,039.78. Following the completion of the transaction, the chief accounting officer owned 139,088 shares of the company’s stock, valued at $5,254,744.64. The trade was a 0.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 71,841 shares of company stock valued at $2,722,655. 6.30% of the stock is currently owned by company insiders.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.